Financial Contrast: GoodRx (NASDAQ:GDRX) and SBC Medical Group (NASDAQ:SBC)

GoodRx (NASDAQ:GDRXGet Free Report) and SBC Medical Group (NASDAQ:SBCGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for GoodRx and SBC Medical Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GoodRx 3 8 5 0 2.13
SBC Medical Group 1 0 2 0 2.33

GoodRx presently has a consensus target price of $3.98, suggesting a potential upside of 84.29%. SBC Medical Group has a consensus target price of $8.50, suggesting a potential upside of 103.84%. Given SBC Medical Group’s stronger consensus rating and higher probable upside, analysts clearly believe SBC Medical Group is more favorable than GoodRx.

Volatility and Risk

GoodRx has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Valuation & Earnings

This table compares GoodRx and SBC Medical Group”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GoodRx $796.85 million 0.93 $30.44 million $0.09 24.00
SBC Medical Group $173.61 million 2.46 $50.99 million $0.49 8.51

SBC Medical Group has lower revenue, but higher earnings than GoodRx. SBC Medical Group is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

63.8% of GoodRx shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 4.5% of GoodRx shares are held by insiders. Comparatively, 89.5% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares GoodRx and SBC Medical Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GoodRx 3.82% 9.31% 4.38%
SBC Medical Group 29.37% 20.76% 15.67%

Summary

SBC Medical Group beats GoodRx on 9 of the 14 factors compared between the two stocks.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

About SBC Medical Group

(Get Free Report)

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.